SafeBeat
Guiding cardiac therapeutics - all from your phone
San Francisco, United States · Founded 2020 · $1.1M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2020
- Website
- safebeat.com
- Total Funding
- $1.1M
- Last Round
- $994K GrantAug 2021
- Rounds
- 2
About
38 million people suffer from heart rhythm disorders and are recommended to start medications that can save their lives, but require rigorous ECG monitoring to start and remain on these pills. SafeBeat Rx moves beyond diagnostics to guide these therapeutics, powered by our ML ECG software that integrates with existing FDA-cleared wearables to allow seamless physician approval of drug dosing, all from a mobile phone. We are a team of physicians, engineers, data scientists, and machine learning experts dedicated to using engineering to improve heart health.
Summary
SafeBeat is an EdTech company based in San Francisco, United States, founded in 2020. It has raised $1.1M in total across 2 rounds, most recently a $994K Grant round in Aug 2021. Investors include Y Combinator Continuity Fund and National Heart, Lung, and Blood Institute.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2021
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.

operates in the healthcare industry focusing on biotechnology business
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
